250 related articles for article (PubMed ID: 31366982)
1. Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis.
Liu Y; Zhong GC; Tan HY; Hao FB; Hu JJ
Sci Rep; 2019 Jul; 9(1):11124. PubMed ID: 31366982
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic Fatty Liver Disease Associates With Increased Overall Mortality and Death From Cancer, Cardiovascular Disease, and Liver Disease in Women but Not Men.
Hwang YC; Ahn HY; Park SW; Park CY
Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1131-1137.e5. PubMed ID: 29158157
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission.
Wild SH; Walker JJ; Morling JR; McAllister DA; Colhoun HM; Farran B; McGurnaghan S; McCrimmon R; Read SH; Sattar N; Byrne CD;
Diabetes Care; 2018 Feb; 41(2):341-347. PubMed ID: 29167212
[TBL] [Abstract][Full Text] [Related]
4. Association Between Diabetes Mellitus and All-Cause and Cardiovascular Mortality Among Individuals With Ultrasound-Defined Non-Alcoholic Fatty Liver Disease.
Wu W; Xiang J; Chen X
Front Endocrinol (Lausanne); 2021; 12():773342. PubMed ID: 34992579
[TBL] [Abstract][Full Text] [Related]
5. Lean non-alcoholic fatty liver disease and the risk of all-cause mortality: An updated meta-analysis.
Wongtrakul W; Charatcharoenwitthaya N; Charatcharoenwitthaya P
Ann Hepatol; 2024; 29(3):101288. PubMed ID: 38278181
[TBL] [Abstract][Full Text] [Related]
6. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.
Mantovani A; Csermely A; Petracca G; Beatrice G; Corey KE; Simon TG; Byrne CD; Targher G
Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):903-913. PubMed ID: 34555346
[TBL] [Abstract][Full Text] [Related]
7. Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors.
Mann JP; Carter P; Armstrong MJ; Abdelaziz HK; Uppal H; Patel B; Chandran S; More R; Newsome PN; Potluri R
PLoS One; 2020; 15(10):e0241357. PubMed ID: 33108366
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States.
Golabi P; Paik JM; Kumar A; Al Shabeeb R; Eberly KE; Cusi K; GunduRao N; Younossi ZM
Metabolism; 2023 Sep; 146():155642. PubMed ID: 37380016
[TBL] [Abstract][Full Text] [Related]
9. A Meta-analysis on Associated Risk of Mortality in Nonalcoholic Fatty Liver Disease.
Fu CE; Ng CH; Yong JN; Chan KE; Xiao J; Nah B; Bong SHS; Win KM; Bwa AH; Lim WH; Tan DJH; Zeng RW; Chew N; Teng MLP; Siddiqui MS; Oben JA; Sanyal AJ; Wong VW; Noureddin M; Muthiah M
Endocr Pract; 2023 Jan; 29(1):33-39. PubMed ID: 36273685
[TBL] [Abstract][Full Text] [Related]
10. Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis.
Morrison AE; Zaccardi F; Khunti K; Davies MJ
Liver Int; 2019 Mar; 39(3):557-567. PubMed ID: 30358050
[TBL] [Abstract][Full Text] [Related]
11. Association of non-alcoholic fatty liver disease and all-cause mortality in hospitalized cardiovascular disease patients: A systematic review and meta-analysis.
Saokaew S; Kanchanasurakit S; Thawichai K; Duangprom P; Wannasri M; Khankham S; Kositamongkol C; Chaiyakunapruk N; Phisalprapa P
Medicine (Baltimore); 2021 Feb; 100(5):e24557. PubMed ID: 33592910
[TBL] [Abstract][Full Text] [Related]
12. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.
Targher G; Byrne CD; Lonardo A; Zoppini G; Barbui C
J Hepatol; 2016 Sep; 65(3):589-600. PubMed ID: 27212244
[TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease.
Chinnadurai R; Ritchie J; Green D; Kalra PA
Nephrol Dial Transplant; 2019 Mar; 34(3):449-457. PubMed ID: 29390103
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes.
Mantovani A; Mingolla L; Rigolon R; Pichiri I; Cavalieri V; Zoppini G; Lippi G; Bonora E; Targher G
Int J Cardiol; 2016 Dec; 225():387-391. PubMed ID: 27768965
[TBL] [Abstract][Full Text] [Related]
15. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Taylor RS; Taylor RJ; Bayliss S; Hagström H; Nasr P; Schattenberg JM; Ishigami M; Toyoda H; Wai-Sun Wong V; Peleg N; Shlomai A; Sebastiani G; Seko Y; Bhala N; Younossi ZM; Anstee QM; McPherson S; Newsome PN
Gastroenterology; 2020 May; 158(6):1611-1625.e12. PubMed ID: 32027911
[TBL] [Abstract][Full Text] [Related]
16. Surrogate scores of advanced fibrosis in NAFLD/NASH do not predict mortality in patients with medium-to-high cardiovascular risk.
Delgado GE; Kleber ME; Moissl AP; Yazdani B; Kusnik A; Ebert MP; März W; Krämer BK; Lammert A; Teufel A
Am J Physiol Gastrointest Liver Physiol; 2021 Sep; 321(4):G252-G261. PubMed ID: 34132110
[TBL] [Abstract][Full Text] [Related]
17. Daytime napping and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis of prospective cohort studies.
Zhong G; Wang Y; Tao T; Ying J; Zhao Y
Sleep Med; 2015 Jul; 16(7):811-9. PubMed ID: 26051864
[TBL] [Abstract][Full Text] [Related]
18. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis.
Wu S; Wu F; Ding Y; Hou J; Bi J; Zhang Z
Sci Rep; 2016 Sep; 6():33386. PubMed ID: 27633274
[TBL] [Abstract][Full Text] [Related]
19. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.
Simon TG; Roelstraete B; Khalili H; Hagström H; Ludvigsson JF
Gut; 2021 Jul; 70(7):1375-1382. PubMed ID: 33037056
[TBL] [Abstract][Full Text] [Related]
20. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
Ekstedt M; Hagström H; Nasr P; Fredrikson M; Stål P; Kechagias S; Hultcrantz R
Hepatology; 2015 May; 61(5):1547-54. PubMed ID: 25125077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
